The Hindu Business Line : Ind-Swift to enter critical health care segments

IND-SWIFT Ltd, a research driven pharmaceutical company, is set to make a foray into fast growing and critical health care segments in the coming years by creating exclusive marketing divisions to handle a slew of new products.

The company has immediate plans to enter the three care segments of anaesthesiology, oncology and surgery, with a new marketing division having been launched for the new products.

The division, named `Resurgence', will be uncorking its new products in three phases, with the first phase envisaging launch of anaesthesiology products and the second and third phases involving introduction of oncology products and innovative surgical drugs respectively.

This will be the company's fifth marketing division, the other four focussing on specific therapeutic segments.

Latest surveys have shown that while the estimated Rs 40-crore market for anaesthesiology products is growing at 19 per cent, oncology and surgical drugs have a market of Rs 100 crore and Rs 170 crore in India.

According to a senior company official, Ind-Swift is targeting a sales turnover of Rs 15 crore, Rs 25 crore and Rs 50 crore in the first three years of the operation of its new marketing division respectively.

"Special focus will be laid on the oncology segment, as ten to twelve products are at present at different stages of developments for launch in the next six to 12 months. As a backward integration, the molecules for the launch of the products in this segment are assured through the company-promoted API entity, Ind-Swift Laboratories, which specialises in developing non-infringing processes," the official said.

After this, the company intends to get into other high-value niche segments such as nephrology and neuropsychiatry and later into the medical devices segments, especially orthopaedic and dental equipment.

"The company plans to have nine marketing divisions to handle the different segments. With the introduction of the new products, we are looking at a sales turnover of Rs 325 crore in the next three years," according to the official.

As part of its plans to compete internationally, the company is focussing on filing patents by developing non-infringing process of finished dosage form based on Novel Drug Delivery Systems (NDDS) and developing non-infringing alternate manufacturing processes for APIs. It has already filed patents for two of its products based on NDDS.

More Stories on : Outlook | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page